As of 2026-04-18, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -5.16. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 2,290.23 mil USD. SRPT's TTM EBITDA according to its financial statements is -443.97 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 27.3x | 16.4x |
| Forward P/E multiples | 17.2x - 35.5x | 26.0x |
| Fair Price | (73.17) - (115.62) | (89.91) |
| Upside | -439.5% - -636.5% | -517.2% |
| Date | EV/EBITDA |
| 2026-04-17 | -5.08 |
| 2026-04-16 | -5.07 |
| 2026-04-15 | -5.20 |
| 2026-04-14 | -5.30 |
| 2026-04-13 | -5.22 |
| 2026-04-10 | -5.07 |
| 2026-04-09 | -5.32 |
| 2026-04-08 | -5.24 |
| 2026-04-07 | -5.52 |
| 2026-04-06 | -5.45 |
| 2026-04-02 | -5.56 |
| 2026-04-01 | -5.30 |
| 2026-03-31 | -5.21 |
| 2026-03-30 | -4.91 |
| 2026-03-27 | -4.78 |
| 2026-03-26 | -5.19 |
| 2026-03-25 | -5.68 |
| 2026-03-24 | -4.23 |
| 2026-03-23 | -4.25 |
| 2026-03-20 | -4.01 |
| 2026-03-19 | -4.00 |
| 2026-03-18 | -4.12 |
| 2026-03-17 | -4.04 |
| 2026-03-16 | -4.00 |
| 2026-03-13 | -3.94 |
| 2026-03-12 | -4.09 |
| 2026-03-11 | -4.22 |
| 2026-03-10 | -4.24 |
| 2026-03-09 | -4.23 |
| 2026-03-06 | -4.01 |
| 2026-03-05 | -3.90 |
| 2026-03-04 | -3.87 |
| 2026-03-03 | -3.82 |
| 2026-03-02 | -3.92 |
| 2026-02-27 | -4.03 |
| 2026-02-26 | -4.19 |
| 2026-02-25 | -4.55 |
| 2026-02-24 | -4.52 |
| 2026-02-23 | -4.35 |
| 2026-02-20 | -4.53 |
| 2026-02-19 | -4.46 |
| 2026-02-18 | -4.41 |
| 2026-02-17 | -4.29 |
| 2026-02-13 | -4.27 |
| 2026-02-12 | -4.18 |
| 2026-02-11 | -4.31 |
| 2026-02-10 | -4.40 |
| 2026-02-09 | -4.39 |
| 2026-02-06 | -4.44 |
| 2026-02-05 | -4.09 |